Amgen (AMGN) Tops Q4 EPS by 56c, Beats on Revenue; Offers FY26 Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $5.29, $0.56 better than the analyst estimate of $4.73. Revenue for the quarter came in at $9.9 billion versus the consensus estimate of $9.46 billion.

GUIDANCE:

Amgen sees FY2026 EPS of $21.60-$23.00, versus the consensus of $22.10. Amgen sees FY2026 revenue of $37-38.4 billion, versus the consensus of $37.1 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group